Książki na temat „Monoamides”

Binda, Claudia, red. Monoamine Oxidase. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2643-6.

Oreland, Lars, i Brian A. Callingham, red. Monoamine Oxidase Enzymes. Vienna: Springer Vienna, 1987. http://dx.doi.org/10.1007/978-3-7091-8901-6.

National Institutes of Health (U.S.), red. Low monoamine (LMA) diet. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1989.

Szelenyi, I., red. Inhibitors of Monoamine Oxidase B. Basel: Birkhäuser Basel, 1993. http://dx.doi.org/10.1007/978-3-0348-6348-3.

Roberts, M. H. T. The central and antinociceptive actions of the monoamines. Birmingham: University of Birmingham, 1986.

H, Yasuhara, red. Monoamine oxidase: Basic and clinical aspects. Utrecht, Netherlands: VSP, 1993.

Van Bockstaele, Elisabeth J., red. Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7940-6.

H, Kennedy Sidney, red. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, 1994.

Ebrahimi, Soltan Ahmed. Characterisation of guinea pig liver monoamine oxidase. Portsmouth: University of Portsmouth, School of Pharmacy and Biomedical Science, 1995.

G, Priest R., red. Depression and reversible monoamine oxidase inhibitors: New perspectives. London: Royal College of Psychiatrists, 1989.

Michel, Bourin, red. Les IMAO. Paris: Ellipses-Marketing, 1993.

Yu, Qinghui. Developmental Monoamine Signaling Impacts Adult Affective and Aggressive Behaviors. [New York, N.Y.?]: [publisher not identified], 2012.

Next generation antidepressants: Moving beyond monoamines to discover novel treatment strategies for mood disorders. Cambridge: Cambridge University Press, 2010.

D, Burrows Graham, i Da Prada M, red. Reversible MAO-A inhibitors as antidepressants: Basic advances and clinical perspectives. Wien: Springer-Verlag, 1989.

M, Yu Peter, Boulton A. A i Tipton Keith F, red. Current neurochemical and pharmacological aspects of biogenic amines: Their function, oxidative deamination, and inhibition. Amsterdam: Elsevier, 1995.

M, Yu Peter, Boulton A. A i Tipton Keith F, red. Current neurochemical and pharmacological aspects of biogenic amines: Their function, oxidative deamination, and inhibition. Amsterdam: Elsevier, 1995.

1941-, Szelenyi I., red. Inhibitors of monoamine oxidase B: Pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser, 1993.

F, Tipton Keith, red. Amine oxidases: Function and dysfunction : proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22-25, 1992. Wien: Springer-Verlag, 1994.

Biogenic monoamines and their metabolites in the urine, plasma, and cerebrospinal fluid of normal, psychiatric, and neurological subjects. Boca Raton, Fla: CRC Press, 1990.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), red. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

Yu, Wai Haung. Desferrioxamine analysis by high performance liquid chromatography, stability and metabolic inhibition by monoamine oxidase inhibitors. Ottawa: National Library of Canada, 1994.

Zeric, Tamara. Peri-adolescent monoamine interference alters behavioral response to cocaine and associated dopamine dynamics in adulthood. [New York, N.Y.?]: [publisher not identified], 2022.

Karpowicz, Richard. I. Advanced Fluorescent False Neurotransmitters for the Study of Monoamine Transporter Activity and Synaptic Transmission. [New York, N.Y.?]: [publisher not identified], 2013.

Umberto, Di Porzio, Pernas-Alonso Roberto i Perrone-Capano Carla, red. Development of dopaminergic neurons. Austin: R.G. Landes Co., 1999.

IBRO International Symposium on Neuroendocrinology (1985 Leningrad, R.S.F.S.R.). IBRO International Symposium on Neuroendocrinology: "Peptide and monoamine neurohormones in neuroendocrine regulation", Leningrad, August 19--23, 1985 : abstracts. Redaktorzy Polenov Andreĭ Lʹvovich, Akademii͡a︡ nauk SSSR, International Brain Research Organization. Soviet National Committee. i Institut ėvoli͡u︡t͡s︡ionnoĭ fiziologii i biokhimii im. I.M. Sechenova. Leningrad: [s.n.], 1985.

Rúzsás, Csilla. Maturation and aging of neuroendocrine functions: The role of monoaminergic neurons and of the pineal gland. Budapest: Akadémiai Kiadó, 2001.

Praag, Herman M. van 1929-, Plutchik Robert i Apter Alan, red. Violence and suicidality: Perspectives in clinical and psychobiological research. New York: Brunner/Mazel, 1990.

Torre, J. de la. Dynamics of Brain Monoamines. Springer, 2012.

Torre, J. de la. Dynamics of Brain Monoamines. Springer, 2012.

Torre, J. de la. Dynamics of Brain Monoamines. Springer London, Limited, 2012.

Isocyclische Monoamine. Wyd. 4. Springer, 2029.

Roze, Emmanuel, i Nenad Blau. Biogenic Monoamine Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199972135.003.0031.

Low monoamine (LMA) diet. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1988.

John P.M. Finberg (Editor), Moussa B.H. Youdim (Editor), Peter Riederer (Editor) i K. F. Tipton (Editor), red. MAO-The Mother of All Amine Oxidases (Journal of Neural Transmission Supplementa). Springer, 2003.

Monoamine Oxidase and their Inhibitors. Elsevier, 2011. http://dx.doi.org/10.1016/c2009-0-01862-5.

Monoamine Oxidase and Its Inhibition. Wiley & Sons, Incorporated, John, 2009.

Riederer, Peter, i Moussa Youdim. Monoamine Oxidases and Their Inhibitors. Elsevier Science & Technology Books, 2011.

Binda, Claudia. Monoamine Oxidase: Methods and Protocols. Springer, 2022.

Knight, Julie, i G. E. W. Wolstenholme. Monoamine Oxidase and Its Inhibition. Wiley & Sons, Limited, John, 2008.

Riederer, Peter, i Moussa Youdim. Monoamine Oxidases and Their Inhibitors. Elsevier Science & Technology Books, 2011.

Jes, Olesen, i Edvinsson Lars, red. Headache pathogenesis: Monoamines, neuropeptides, purines, and nitric oxide. Philadelphia: Lippincott-Raven, 1997.

Tipton, K. F., M. B. H. Youdim i C. J. Barwell. Amine Oxidases: Function and Dysfunction : Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22-25, 1992 (Journal of Neural Transmission Supplementum). Springer-Verlag Telos, 1994.

1938-, Lieberman A. N., red. Monoamine oxidase inhibitors in neurological diseases. New York: M. Dekker, 1994.

1939-, Oreland L., Callingham B. A i Workshop on Amine Oxidases (2nd : 1986 : Biomedical Center, Uppsala University), red. Monoamine oxidase enzymes: Review and overview. Wien: Springer-Verlag, 1987.

Nagatsu, Hasan Parvez i Yasuhara. Monoamine Oxidase: Basic and Clinical Aspects. Taylor & Francis Group, 1993.